DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Pentifylline

Pentifylline

  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al

    (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al

  • 勃起不能治療準則 賴依伶 毛箴言 林口長庚紀念醫院藥劑科 台北藥劑組 本稿譯自 European Association of Urology:GUIDELINES on ERECTILE DYSFUNCTION

    勃起不能治療準則 賴依伶 毛箴言 林口長庚紀念醫院藥劑科 台北藥劑組 本稿譯自 European Association of Urology:GUIDELINES on ERECTILE DYSFUNCTION

  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

  • Customs Tariff - Schedule

    Customs Tariff - Schedule

  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr

    (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr

  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al

  • Stembook 2018.Pdf

    Stembook 2018.Pdf

  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf

    WHO-EMP-RHT-TSN-2018.1-Eng.Pdf

  • 2021 Equine Prohibited Substances List

    2021 Equine Prohibited Substances List

  • Wo 2007/120485 A2

    Wo 2007/120485 A2

  • Oxpentifylline and Cetiedil Citrate Improve Deformability of Dehydrated Sickle Cells

    Oxpentifylline and Cetiedil Citrate Improve Deformability of Dehydrated Sickle Cells

  • Medical Product Quality Report – COVID-19 Issues

    Medical Product Quality Report – COVID-19 Issues

  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs

    Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs

  • Medical Product Quality Report – COVID-19 Issues

    Medical Product Quality Report – COVID-19 Issues

  • Systemic Therapy with Conventional and Novel Immunomodulatory Agents for Ocular Inflammatory Disease

    Systemic Therapy with Conventional and Novel Immunomodulatory Agents for Ocular Inflammatory Disease

  • 'Cerebroactive' Drugs Clinical Pharmacology and Therapeutic Role in Cerebrovascular Disorders

    'Cerebroactive' Drugs Clinical Pharmacology and Therapeutic Role in Cerebrovascular Disorders

Top View
  • Transdermal Device Containing
  • WO 2018/055211 Al 29 March 2018 (29.03.2018) W !P O PCT
  • Pharmaabkommen A1 E
  • Non-Target Screening ‒ a Powerful Tool for Selecting Environmental Pollutants
  • (12) United States Patent (10) Patent No.: US 8,354,116 B2 Carter Et Al
  • Customs Tariff - Schedule Xxi - 1
  • Pentoxifylline, Pentifylline, and Interferons Decrease Type I
  • WO 2015/120110 A2 13 August 2015 (13.08.2015) P O P C T
  • Isoxsuprine Elisa Kit Instructions Product #102219 & 102216 Forensic Use Only
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
  • ICD-10-CM TABLE of DRUGS and CHEMICALS 2020
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0292280 A1 Zachar (43) Pub
  • Pentoxifylline Downregulates Profibrogenic Cytokines And
  • Investigação Da Eficácia Terapêutica De Compostos Com Atividade Anti
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
  • Supplementary Table 1. All Compounds Causing BLI Enhancement
  • [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
  • Harmonized Tariff Schedule of the United States (2006) (Rev


© 2024 Docslib.org    Feedback